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ABSTRACT
Ulcerative colitis (UC) in children is increasing. The range
of treatments available has also increased too but
around 1 in 4 children still require surgery to control
their disease. An up-to-date understanding of treatments
is essential for all clinicians involved in the care of UC
patients to ensure appropriate and timely treatment
while minimising the risk of complications and side
effects.
INTRODUCTION
Within the diagnostic label of inﬂammatory bowel
disease (IBD), ulcerative colitis (UC) is typically
characterised by diffuse mucosal inﬂammation,
limited to the colon, with conﬂuent inﬂammation
extending proximally from the rectum to varying
severity and extent. In children, it is well recog-
nised however, that UC typically affects all or most
of the colon (extensive or pan-colitis), whereas
adults more often present with localised distal
disease (proctitis).1 Recently, the paediatric Porto
criteria for the diagnosis of IBD have been revised
to take account of diagnostic advances, for
example, in imaging techniques, and also to help
correctly assign patients to the differing IBD sub-
groups.2 In the paediatric age group, up to 10% of
cases cannot be assigned to as either UC or Crohn’s
despite comprehensive assessment. These are classi-
ﬁed as IBD unclassiﬁed, although in practice, cur-
rently, they are most commonly treated along the
same lines as UC.
DIAGNOSTIC TESTS FOR SUSPECTED
INFLAMMATORY BOWEL DISEASE
The majority of children with ulcerative colitis (UC)
present with the characteristic features of diarrhoea,
blood in stools and abdominal pain, which indicate
a colitic process. Blood tests (full blood count,
erythrocyte sedimentation rate, C reactive protein,
liver function tests and albumin) will show abnor-
malities in around 80% of cases in inﬂammatory
bowel disease (IBD), and thus, form part of the
initial assessment of suspected cases.3 Faecal tests
such as calprotectin are useful adjuncts to these
blood tests in identifying inﬂammation, but levels
can be elevated by causes apart from IBD.4
In cases with suspected IBD, following exclusion
of an infective cause, both upper and lower gastro-
intestinal (GI) (ileocolonic) endoscopy are required.
Imaging of the small bowel is also recommended.2
With the more widespread availability of magnetic
resonance enterography this is now the modality of
choice, when available, for differentiating UC from
Crohn’s disease (CD). It is important to exclude
Clostridium difﬁcile (C. diff ) infection in the
differential diagnosis of IBD initially and exclude
C. diff infection as the cause of a disease ‘ﬂare’.
Despite recommendations to screen for C. diff in
these situations, it can often be difﬁcult in practice
as this test has not been historically widely per-
formed in children.
Extraintestinal manifestations (EIMs) can occur
in 6%–17% of patients with UC at diagnosis, and
can increase with disease evolution to nearly 50%.
EIMs can affect joints (arthritis), liver (primary
sclerosing cholangitis, which affects 1.6% of cases
of paediatric IBD at 10 years, autoimmune hepa-
titis), skin (pyoderma gangrenosum) and eyes
(uveitis).5 Sclerosing cholangitis can be associated
with progressive liver disease and cholangicarci-
noma.6 Furthermore, there is an increased risk of
colonic dysplasia in sclerosing cholangitis associated
UC.7 Thus, in these cases, surveillance colonoscopy
will need to be initiated earlier (possibly into the
paediatric age range depending on age at diagnosis)
and followed more frequently.
CLINICAL SCORING WITH THE PAEDIATRIC
ULCERATIVE COLITIS ACTIVITY INDEX
The Paediatric Ulcerative Colitis Activity Index
(PUCAI) (table 1) has been devised as a clinical
score of disease severity, which should now be used
by all paediatricians looking after patients with UC
to objectively assess their disease. By differentially
weighting the severity of the main clinical features
of UC (rectal bleeding, stool frequency and consist-
ency, abdominal pain and general activity levels), a
score between 0 and 85 can be derived.8 This can
then be used to record disease severity at a point
in time plus measure the response to therapy.
A PUCAI score of <10 denotes remission, 10–30
denotes mild disease, 35–60 denotes moderate
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Summary points
▸ The management of ulcerative colitis (UC)
requires an understanding of the available
medications and their side effects.
▸ The Paediatric Ulcerative Colitis Activity Index is
a useful tool for recording disease severity and
its changes over time.
▸ Paediatricians need to be aware of the risks
associated with acute severe colitis and the
need for appropriate and timely escalation of
medical management and the role of surgery in
some cases.
▸ Recognition and treatment of iron deﬁciency
(and other nutritional deﬁcits) is important for
the general well-being of children with UC.
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disease, while a score of ≥65 represents acute severe colitis
(ASC), which is a medical emergency, and thus, recommended
management follows a distinct pathway.
The clinical features of severe UC (ASC) include the typical
symptoms of bloody diarrhoea (usually ≥6 a day with nocturnal
defaecation), abdominal pain and reduced activity. In addition,
there may be further systemic symptoms of vomiting, tachycar-
dia and fever, which can be accompanied by life-threatening
toxic dilation of the colon. The recognition of ASC is of vital
importance, and should be considered a medical emergency with
immediate referral to a paediatric gastroenterology unit with
paediatric surgical support being essential. Subsequent repeat
PUCAI scoring is very helpful in monitoring disease activity and
the response to therapy (see below).
Medical management of UC
The treatment recommendations are based on the guidelines
produced by the National Institute for Health and Care
Excellence and the joint guidelines produced by the European
Crohn’s and Colitis Organisation (ECCO) and European Society
for Paediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN).9–11 These guidelines provide very useful and com-
prehensive algorithms, which cover most common clinical
eventualities.
Most patients with UC can be treated on an outpatient basis,
but with hospitalisation necessary for ASC. The main aim of
treatment of UC in children is to achieve maximum possible
symptomatic control with minimal side effects, while allowing
children to function as normally as possible. The target for treat-
ment increasingly is also looking at intestinal healing beyond
simple symptomatic control to try and reduce the risk of long-
term complications and surgery.1 2 Treatments can be broadly
considered as those used to induce remission (at diagnosis or for
a subsequent ﬂare), such as 5-aminosalicylic acid (5-ASA) agents,
corticosteroids and biologics, and those used for long-term
maintenance of remission such as 5-ASA agents, biologics and
thiopurines.
5-ASA AGENTS
The mainstay of therapy for mild-to-moderate UC is sulfasala-
zine and other 5-ASA agents (eg, mesalazine). These agents are
effective in inducing remission and also in maintaining remis-
sion for patients with mild and some with moderate disease.13
5-ASA preparations are generally preferred to sulfasalazine due
to a superior side effect proﬁle combined with similar efﬁcacy.
However, in younger children (preschool), the absence of a
liquid preparation for 5-ASA means that sulfasalazine will often
be used. 5-ASA preparations are available as granules, and are,
thus, useful for those unable to swallow tablets such as children
of primary school age. A summary of available preparations and
their licencing status is given in table 2.
Oral mesalazine and sulfasalazine are usually given in divided
doses, but there is evidence from adult studies that appropriately
formulated 5-ASA is equally effective when given once daily.14
The generally benign side-effect proﬁle of 5-ASAs has also
resulted in a tendency towards rather higher dosing. The main-
tenance dose should be similar to the dose used for induction
therapy, although the dose can be reduced after a period of sus-
tained remission. Topical 5-ASA (suppositories or enemas) are
effective in mild-to-moderate distal UC, and usually combining
oral and enema therapy is more effective than either treatment
alone for extensive as well as distal UC.15 Lack of response to
mesalazine within 2–4 weeks is an indication to consider treat-
ment with corticosteroids.
CORTICOSTEROIDS
The majority of patients with moderate-to-severe UC achieve
remission on treatment with oral steroids. However, steroid
treatment is not advised for maintenance of remission. The dose
of prednisone/prednisolone should be 1 mg/kg up to 40 mg
Table 1 Paediatric Ulcerative Colitis Activity Index (PUCAI)8
Item Points
(1) Abdominal pain
No pain 0
Pain can be ignored 5
Pain cannot be ignored 10
(2) Rectal bleeding
None 0
Small amount only, in <50% of stools 10
Small amount with most stools 20
Large amount (>50% of stool content) 30
(3) Stool consistency of most stools
Formed 0
Partially formed 5
Completely unformed 10
(4) Number of stools per 24 h
0–2 0
3–5 5
6–8 10
>8 15
(5) Nocturnal stools (any episode causing wakening)
No 0
Yes 10
(6) Activity level
No limitation of activity 0
Occasional limitation of activity 5
Severely restricted activity 10
PUCAI total (0–85)
PUCAI score <10, remission; 10–34, mild; 35–64, moderate; ≥65, severe.
Table 2 Commonly used mesalazine preparations
Drug Formulation Optimal drug release pH Site of drug release
Asacol Enteric coated with Eudragit S pH-dependent delayed release (>7) Terminal ileum and colon
Ipocol Enteric coated with Eudragit S >7 Terminal ileum and colon
Octasa Enteric coated with Eudragit S pH-dependent delayed release (>7) Terminal ileum and colon
Pentasa Ethyl cellulose coated microgranules Diffusion through semipermeable membrane (enteral pH) Duodenum to colon
Salofalk Tablets: enteric coated with Eudragit L;
Granules: Eudragit L plus matrix granule structure
pH-dependent delayed release (>6)
Granules have extra delayed release
Terminal ileum and colon
Licensed use: Asacol (all preparations) and Salofalk enema are not licensed for use in children under 18 years; Salofalk suppositories, Pentasa tablets and suppositories are not licensed
for use in children under 15 years; Pentasa granules and Salofalk granules not licensed for use in children under 6 years.
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once daily in most children. A single total dose in the morning
is advisable to reduce potential harmful suppression of growth.
There are no universally accepted steroid-tapering protocols,
but the ECCO paediatric UC guideline provides a practical
10-week reduction scheme (table 3).11 Steroid dependency is
deﬁned as response or remission with corticosteroid treatment,
but recurrence of symptoms when the dose is lowered or within
3 months following complete taper, or if steroids cannot be
stopped within 14–16 weeks. Children with severe UC will need
intravenous steroid treatment (see below). Steroid dependency
can be avoided by escalating maintenance therapy. For distal
disease, this typically means a 5-ASA rather than steroid enema,
whereas for more extensive colitis, oral beclomethasone dipro-
pionate, a corticosteroid with topical action, can be
considered.16
THIOPURINES (AZATHIOPRINE AND 6-MERCAPTOPURINE)
Azathioprine and 6-mercaptopurine (6-MP) are purine analo-
gues commonly used in the treatment of steroid-dependent IBD
and in children with very severe initial presentation of UC. The
therapeutic effect of thiopurines may take up to 10–14 weeks
after the start of treatment. The recommended dose is 2.5 mg/kg
of azathioprine and 1–1.5 mg/kg of 6-MP, in a single daily dose.
The most recent recommendation is to start on the maximum
dose of thiopurine with no need to ‘build’ up the dose as was
practiced historically.11 Common side effects include headache,
rash and GI disturbance. Some patients experience an inﬂuenza-
like illness, and pancreatitis occurs in between 1% and 4% of
patients. Patients should be informed of the beneﬁts of treat-
ments and how they are balanced against the side-effect proﬁle,
including a small, but increased, risk of malignancy most
notably lymphoma.
The determination of thiopurines methyltransferase (TPMT)
genotype or phenotype is recommended to identify patients at
greater risk of early profound myelosuppression due to homozy-
gote mutant/very low TPMT activity status. It is the authors’
practice to half the recommended dose in heterozygous patients
or in those with low (but not very low) enzyme activity.
Thiopurines should not be used in children who are homozy-
gous for TPMT polymorphisms or those with extremely low
TPMTactivity. Myelosuppression may still occur in the presence
of normal TPMT activity, and therefore, regular monitoring of
blood counts and liver tests are recommended in all cases.
Measurement of thiopurine metabolites, 6-methyl mercaptopur-
ine and 6-thioguanine is helpful to assess compliance and opti-
misation of the therapy. A suggested practice-based algorithm
for using these metabolites is shown in ﬁgure 1.
ANTI-TUMOUR NECROSIS FACTOR ANTIBODIES
Inﬂiximab, adalimumab and golimumab are the anti-tumour
necrosis factor alpha agents available in the UK for the treat-
ment of UC in adults, but the mainstay of paediatric practice is
with inﬂiximab only. Golimumab and adalimumab do not have
the marketing authorisation in the UK for the treatment of UC
in children. Inﬂiximab should be considered for treatment of
children with chronically active or steroid-dependent UC,
uncontrolled by 5-ASA and thiopurines. Inﬂiximab may also be
considered for steroid-refractory disease and acute severe
disease. Measuring inﬂiximab levels and antibodies to inﬂiximab
can optimise treatment when patients fail to respond to therapy
either after initial induction treatment or at follow-up. There is
evidence from adult studies that combining inﬂiximab with a
thiopurine improves effect in patients with UC, but the efﬁcacy
of combination treatment should be weighed against the risk of
side effects, including an increased relative risk of lymphoma.17
Table 3 Steroid tapering table
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11
60* 50 40 35 30 25 20 15 10 5 0
50* 40 40 35 30 25 20 15 10 5 0
45* 40 40 35 30 25 20 15 10 5 0
40 40 30 30 25 25 20 15 10 5 0
35 35 30 30 25 20 15 15 10 5 0
30 30 30 25 20 15 15 10 10 5 0
25 25 25 20 20 15 15 10 5 5 0
20 20 20 15 15 12.5 10 7.5 5 2.5 0
15 15 15 12.5 10 10 7.5 7.5 5 2.5 0
Prednisolone tapering plan. The daily milligram (mg) dose is changed weekly (week) according to this plan.11
*The initial recommended prednisolone dose is 1 mg/kg/day maximum 40 mg/day except for cases discharged following acute severe colitis where higher doses up to 60 mg/day could
be used.
Figure 1 Suggested pathway for reacting to thiopurine metabolite
results. This algorithm is designed predominantly to help patients with
active disease as we assume patients in remission would not routinely
have levels measured. *The majority of patients with a raised 6-methyl
mercaptopurine (6-MMP) need no action taken unless there is evidence
of a transaminitis. The established ranges for 6-thioguanine (6-TGN)
levels and 6-MMP commonly used in the UK are 235–450 pmol (Purine
Research Laboratory at St Thomas, London). Low and high in the ﬁgure
refer to values lying outside these ranges. Allopurinol and dose
reduction is used rarely in paediatric practice to help with thiopurine
toleration, but should only be considered in specialist units with
appropriate experience and monitoring arrangements in place.
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COMPLIANCE (ORAL AND RECTAL PREPARATIONS)
Compliance to administering and continuing oral and rectal
drugs can be difﬁcult. Care will be taken by the initially pre-
scribing specialist to choose with the patient and caregiver the
optimal oral preparation (tablets, granules or suspension). As for
rectal preparations, the indicated and best-suited rectal prepar-
ation for distal disease (suppository, enema, foam enema) will
be evaluated, and patients need to be advised on the application
to maximise tolerance and compliance. This is usually best done
by an IBD nurse with a good knowledge of all of the speciﬁc
available products matched with which product will be best
suited to the individual patient.
ANTIBIOTICS/PROBIOTICS
There is not enough evidence to recommend probiotics or anti-
biotics for routine use in UC. There is evidence for the probiotic
Escherichia coli Nissle 1917 for patients with mild UC who are
intolerant to 5-ASA or as adjuvant therapy.18 In pouchitis
(inﬂammation of the pouch created after a colectomy), a com-
bination probiotic (VSL#3) is useful in reducing the risk of
further episodes of pouchitis. More recently, a combination of
antibiotics has been used for paediatric patients resistant to
other treatments with some promising early results.19
NEWER TREATMENT AGENTS
Vedolizumab (humanised monoclonal antibody that speciﬁcally
recognises the α4β7 heterodimer and selectively blocks gut
lymphocyte trafﬁcking), tofacitinib (oral Janus kinase inhibitor)
and etrolizumab (humanised monoclonal antibody targeting the
β7 subunit of the heterodimeric integrins α4β7 and αEβ7) have
shown promising results in the treatment of adult patients with
UC.20–22 Paediatric trials of these agents are awaited. Faecal
microbiota transplantation has shown some success in adult
patients with UC.23 A pilot study in children had shown that
faecal microbiota transplantation via enemas was well tolerated
and safe, but before its extension into clinical practice, further
clinical trial data are needed.24
ACUTE SEVERE UC
A consensus for managing ASC in children constructed by
ECCO has been endorsed by ESPGHAN and the paediatric
Porto IBD working group of ESPGHAN as well as the
IBD working group of BSPGHAN.10 All of these patients
require hospital admission. First-line therapy is with intravenous
steroids—methylprednisolone at a dosage of 1–1.5 mg/kg/day
(up to a maximum of 60 mg/day) given in one or two divided
daily doses.10 The majority of patients will respond to this treat-
ment.25 Of note, 5-ASA medication can cause an acute ‘colitic’
response and should be stopped in ASC and should not be
started in patients who are naïve to 5-ASA until they are in the
recovery phase to avoid any contribution they may be making
to the colitic symptoms.
Timely introduction of second-line therapy is very important
(ﬁgure 2). In children, Turner et al found that sequential PUCAI
scores were effective in identifying those patients requiring a
step up in treatment with second-line (salvage) therapy, reducing
morbidity plus reducing the need for emergency colectomy.26 27
A PUCAI score of >45 on day 3 indicated a likelihood of
Figure 2 Simpliﬁed algorithm of
assessment of children with acute
severe colitis. This simpliﬁed algorithm
emphasises the need for daily
monitoring with the Paediatric
Ulcerative Colitis Activity Index (PUCAI)
and timely escalation of therapy in
non-responsive cases according to
ﬁxed timelines. At day 3 review
progress, at day 5 escalate therapy if
PUCAI is >65.
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steroid failure (negative predictive value 94%, positive predict-
ive value 43%), and a PUCAI score of >65 on day 5 indicated
the need for salvage therapy with a positive predictive value of
100%, speciﬁcity of 94% and negative predictive value of 78%.
Second-line salvage therapy, in the absence of toxic megacolon
(TMC), involves either calcineurin inhibitors (ciclosporin or
tacrolimus) or a biological therapy (inﬂiximab). Traditionally,
intravenous ciclosporin was used, but more recently, inﬂiximab
usage has increased, avoiding the initial need to monitor drug
levels in the acute phase.25 Both can act as a bridge to establish-
ing thiopurines. If previous thiopurine therapy has failed,
however, inﬂiximab may be the preferred treatment as it offers
the option of maintenance in the longer term. Please refer to
consensus paper for more detailed information.10
Surgery should always be discussed at an early stage with the
patient and family depending on individual proﬁles and con-
cerns. Any patient with ASC unresponsive to steroids on day 3
should have a surgical assessment (if not previously done), and
this is mandatory if TMC is suspected. An abdominal X-ray
should be taken. Dilatation of the transverse colon >56 mm
plus signs of toxicity is diagnostic for TMC, with >40 mm sufﬁ-
cient in children <10 years of age.28 Escalating pain in ASC
should lead to an assessment to exclude TMC immediately.
SURGICAL MANAGEMENT OF PAEDIATRIC UC
Surgery is an integral part of the management strategy in
patients with UC. The most common surgery that is carried out
is a subtotal/total colectomy with a temporary stoma. There is
evidence to show that laparoscopic surgery is as safe and effect-
ive as open surgery, but has the added beneﬁt of reduced hos-
pital stay, improved patient experience and improved cosmetic
outcomes.29 30 Restorative surgery can be carried out in 1–3
stage pouch surgery within selected groups of children.
Although pouch surgery offers the comfort of not having a
stoma for life, there are many concerns that should be discussed
to ensure that the child and their parents are aware of the
potential risks, which include faecal incontinence, reduced
fecundity and erectile dysfunction. Pouchitis is one of the more
common problems encountered with antibiotics used as the
mainstay of initial treatment.
Surgery is generally perceived as a last resort when all
medical options have failed, but this perception and fear of the
unknown in conjunction with having a primary stoma makes
this a potentially difﬁcult subject to discuss with children and
adolescents. However, it is clearly recognised that unplanned/
emergency surgery as in ASC along with the feeling of ‘failing’
can have a signiﬁcant psychological impact on young people
and their family, with resultant difﬁculties accepting the stoma
and adapting lifestyles. Therefore, surgery should be discussed
in a timely manner with all patients and their family as a poten-
tial treatment option in a manner that is appropriate to age and
stage of development, particularly if they are steroid dependent
and on multiple immunosuppression or in the acute setting.
NUTRITIONAL CONSIDERATIONS
Nutritional requirements should not be overlooked in ASC;
enteral feeding with regular diet or calorie supplementation is
desirable, although bowel rest is not associated with improved
outcome even after controlling for disease activity. However, if
nutritional requirements cannot be met enterally, parenteral
nutrition should be considered early, particularly if surgery
appears likely and certainly in the case of TMC.
Growth and nutrition are often neglected in patients with UC
as it is generally expected that children with UC will reach their
full growth potential, which will not be affected if there is good
disease control. However, frequent steroid therapy and active
inﬂammation can impact on bone health and growth, which
should be actively monitored and treated if identiﬁed. Calcium
and vitamin D intake should be assessed because of their impact
on bone health, especially in patients who have been on
prolonged steroids. Iron deﬁciency was recently identiﬁed as a
Figure 3 Suggested pathway for diagnosis and treatment of
iron-deﬁciency anaemia. CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; Hb, haemoglobin; Hct, haematocrit; IBD,
inﬂammatory bowel disease; ID, iron deﬁciency; IDA, iron deﬁciency
anaemia; MCV, mean corpuscular volume; PUCAI, Paediatric Ulcerative
Colitis Activity Index; PCDAI, paediatric Crohn’s disease activity index.
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commonly ignored problem in the majority of UK paediatric
patients with UC reviewed as part of the UK IBD audit.25 We,
therefore, have provided a practice-based algorithm to help
teams both identify and treat this problem (ﬁgure 3).
CONCLUSION
The guidelines referenced in this review offer a useful summary
for how to manage UC. They highlight the need for accurate
diagnosis, early initiation of appropriate therapy and ongoing
assessment of disease progress and the side effects of treatment.
Care is often centralised, but awareness of who and when to
refer for assessment both initially and during relapse (particu-
larly for severe colitis) will remain an important part of the
overall management of these children.
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